Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
39448201 2024 Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models. Journal for immunotherapy of cancer Likely relevant Evaluates the combination of alum-anchored IL-12 (mANK-101) with cisplatin and anti-PD-1, demonstrating enhanced antitumor immune responses including T-cell recruitment and macrophage repolarization in murine models. mANK-101; cisplatin; alpha-PD-1 Animal Head and Neck Squamous Cell Carcinoma mANK-101 0/0/0; cisplatin 18/3/11; alpha-PD-1 0/0/0 Awaiting curator check
39461881 2024 Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma. Journal for immunotherapy of cancer Likely relevant The study evaluates anti-PD-1 immunotherapy and an S1P1 inhibitor in murine glioblastoma models, assessing immune phenotypes such as CD8 T cell stemness and cytotoxicity. anti-programmed cell death protein-1 (PD-1); S1P1 inhibitor Animal glioblastoma (GBM) anti-programmed cell death protein-1 (PD-1) 0/0/0; S1P1 inhibitor 0/0/0 Awaiting curator check
39475614 2024 Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer. Science advances Likely relevant The study tests Notch inhibition combined with immune checkpoint blockade in animal models and measures TAM reduction and CTL infiltration. Notch inhibitors; immune checkpoint blockade (ICB) Animal triple-negative breast cancer Notch inhibitors 0/0/0; immune checkpoint blockade (ICB) 0/0/0 Awaiting curator check
39488102 2024 Echinacoside inhibits tumor immune evasion by downregulating inducible PD-L1 and reshaping tumor immune landscape in breast and colorectal cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology Likely relevant Tests Echinacoside treatment in mice and cancer cells, showing it downregulates inducible PD-L1, enhances T cell functions, and reshapes the tumor immune landscape. Echinacoside; anti-PD-1; anti-CTLA-4 Animal Breast and Colorectal Cancer Echinacoside 0/0/0; anti-PD-1 14/36/0; anti-CTLA-4 1/10/7 Awaiting curator check
39500530 2024 WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. Journal for immunotherapy of cancer Likely relevant Investigates the role of WWOX and pharmacological blockade of SCD5 in combination with anti-PD-1 therapy in humanized orthotopic mouse models and in vitro co-cultures, measuring macrophage and CD8 T cell changes. anti-PD-1; SCD5 inhibitor Mixed hepatocellular carcinoma anti-PD-1 14/36/0; SCD5 inhibitor 0/0/0 Awaiting curator check
39515328 2024 Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer cell Likely relevant The study tests CD155 blockade combined with anti-PD-1 therapy in preclinical HCC models and evaluates effects on CD8+ T cell-mediated killing and neutrophil recruitment. anti-PD-1; anti-PD-L1; CD155 antibody Animal hepatocellular carcinoma anti-PD-1 14/36/0; anti-PD-L1 0/15/0; CD155 antibody 0/0/0 Awaiting curator check
39561763 2024 Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity Likely relevant Investigates targeting ERAP in combination with ICB in mouse tumor models, measuring CD8+ T cell and NK cell dependence and checkpoint activity. immune checkpoint blockade (ICB) Animal cancer immune checkpoint blockade (ICB) 0/0/0 Awaiting curator check
39585102 2024 RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome. Oncoimmunology Likely relevant The study is a short report/summary describing preclinical experiments where a RIPK1 inhibitor improves immunotherapy and radiotherapy outcomes. RIPK1 inhibitor; PD-1 blockade; CTLA-4 blockade Animal unspecified RIPK1 inhibitor 0/0/0; PD-1 blockade 0/0/0; CTLA-4 blockade 0/0/1 Awaiting curator check
39629135 2024 SPHK1 promotes HNSCC immune evasion by regulating the MMP1-PD-L1 axis. Theranostics Likely relevant Tests a PD-1 monoclonal antibody in immune-competent mouse models and reports effects on anti-tumor immunity and PD-L1. PD-1 mAb Animal head and neck squamous cell carcinoma PD-1 mAb 0/1/0 Awaiting curator check
39641253 2024 Prevotellaceae Modulates Colorectal Cancer Immune Microenvironment to Assist Anti-PD-L1 Immunotherapy. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology Likely relevant The study experimentally tests anti-PD-L1 immunotherapy in combination with microbiota modulation in mouse models and measures immune cell infiltration and cytokine levels. anti-PD-L1 Mixed colorectal cancer anti-PD-L1 0/15/0 Awaiting curator check
39657664 2024 Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell reports. Medicine Likely relevant Tests lurbinectedin and PD-L1 blockade in SCLC models and clinical samples, measuring changes in STING signaling, MHC expression, CD8+ T cells, and macrophages. lurbinectedin; PD-L1 blockade Mixed small-cell lung cancer lurbinectedin 0/0/0; PD-L1 blockade 0/4/0 Awaiting curator check
39681571 2024 Development of a RIPK1 degrader to enhance antitumor immunity. Nature communications Likely relevant Demonstrates that a novel RIPK1 degrader (LD4172) triggers immunogenic cell death, enhances tumor-infiltrating lymphocytes, and sensitizes tumors to anti-PD1 therapy in mice. LD4172; anti-PD1 Animal Cancer LD4172 0/0/0; anti-PD1 1/1/0 Awaiting curator check
39694700 2024 LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. Journal for immunotherapy of cancer Likely relevant The study tests the effects of Skp2 inhibitors (compound #25) and PD-1/PD-L1 blockade immunotherapy in NSCLC cell lines and in vivo models, measuring immune readouts such as TME phenotype and PD-L1 expression. anti-PD-1; anti-PD-L1; compound #25 Mixed non-small cell lung cancer anti-PD-1 14/36/0; anti-PD-L1 0/15/0; compound #25 0/0/0 Awaiting curator check
39726591 2024 TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC. Frontiers in immunology Likely relevant The study experimentally evaluates the effects of neoadjuvant chemotherapy and immunochemotherapy on immune cell dynamics, TLS density, and T-cell phenotypes in NSCLC patients. PD-1 inhibitor; chemotherapy Patient NSCLC PD-1 inhibitor 0/0/0; chemotherapy 2/0/3 Awaiting curator check
35708739 2023 Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients. Cancer immunology, immunotherapy : CII Likely relevant The study experimentally tests immune checkpoint inhibitors on patient-derived T cells and measures effects on immune checkpoints, T cell phenotypes, and cytokine production. nivolumab; ipilimumab Patient oesophageal adenocarcinoma nivolumab 1/2/4; ipilimumab 1/0/7 Awaiting curator check
36442849 2023 Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1/L1 Response. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant Uses transgenic mouse models to test targeted macrophage ferroptosis and anti-PD-L1 therapy, measuring macrophage polarization, infiltration, and PD-L1 expression. anti-PD-L1 therapy; Man@pSiNPs-erastin Animal Hepatocellular Carcinoma anti-PD-L1 therapy 0/0/0; Man@pSiNPs-erastin 0/0/0 Awaiting curator check
36455783 2023 Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of hepatology Likely relevant Evaluates anti-PD-1 and sorafenib treatment in mouse HCC models and measures immune readouts including tumor-infiltrating CD8+ T cells and chemokine expression. anti-PD-1; sorafenib Animal Hepatocellular Carcinoma anti-PD-1 14/36/0; sorafenib 27/25/7 Awaiting curator check
36563773 2023 Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. Acta biomaterialia Likely relevant Examines chemotherapy-induced tumor RNA nanoparticles and their effects on dendritic cell maturation and T cell infiltration in tumour-bearing animals. chemotherapy Animal colon carcinoma chemotherapy 2/0/3 Awaiting curator check
36579489 2023 Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment. Journal of medicinal chemistry Likely relevant The study tests a novel small-molecule PD-L1 inhibitor (S4-1) in vitro and in vivo and measures its effects on PBMC cytotoxicity toward tumor cells, T-cell activation, and the tumor microenvironment. S4-1 Mixed lung and colorectal cancer S4-1 0/0/0 Awaiting curator check
36596787 2023 Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nature communications Likely relevant This is a clinical trial evaluating neoadjuvant chemoimmunotherapy and antiangiogenesis therapy, measuring dynamic changes in the immune microenvironment and T cell receptor repertoires. camrelizumab; apatinib; S-1; oxaliplatin Patient gastric cancer camrelizumab 0/0/0; apatinib 4/0/0; S-1 2/0/0; oxaliplatin 12/5/2 Awaiting curator check
36631610 2023 γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature Likely relevant The study investigates the effect of immune checkpoint blockade on gamma delta T cell infiltration and reactivity in MMR-deficient colon cancers with HLA class I defects using patient samples and organoids. PD-1 blocker; CTLA-4 blocker Mixed colon cancer PD-1 blocker 0/0/0; CTLA-4 blocker 0/0/0 Awaiting curator check
36649564 2023 Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma. Cancer discovery Likely relevant The study tests pharmacological and genetic targeting combined with immune-checkpoint blockade in vivo, measuring effects on microglia and CD8+ T cell antigen presentation. immune-checkpoint blockade; pharmacologic NR4A2 inhibitor Animal glioblastoma immune-checkpoint blockade 0/0/0; pharmacologic NR4A2 inhibitor 0/0/0 Awaiting curator check
36650022 2023 Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. Journal for immunotherapy of cancer Likely relevant The study experimentally tests statin drugs and anti-PD-1 in murine cancer models and coculture assays, and measures their effects on T-cell killing, activation, and macrophage polarization. simvastatin; lovastatin; anti-PD-1 Mixed head and neck squamous cell carcinoma simvastatin 0/0/0; lovastatin 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
36669362 2023 Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant The study investigates regorafenib and ICI therapy and measures their effects on T cell toxicity, Treg infiltration, and cytokine production. regorafenib; immune checkpoint inhibitor Mixed hepatocellular carcinoma regorafenib 6/3/0; immune checkpoint inhibitor 0/0/0 Awaiting curator check
36707233 2023 Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut Likely relevant Investigates ferroptosis induction and blockade therapies and their impact on cytotoxic T cell and MDSC infiltration in murine tumour models. withaferin A; SB225002; alpha-PD-1 Animal hepatocellular carcinoma and colorectal cancer withaferin A 0/0/0; SB225002 0/0/0; alpha-PD-1 0/0/0 Awaiting curator check
← Previous Page 9 of 15 Next →